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ABSTRACT
The binding modes of some non-platinum metal anticancer complexes, Cp2TiCI2, Cp2ZrCI2,
(CH3)2SnCl2, (C2Hs)2SnCI2, (C2Hs)2SnCI2(phen) (phen=Phenanthroline) and cis-RuCi2(DMSO)3
(DMSO) (cis-RDT) with nucleotides and DNA in aqueous solution at physiological pH values
were investigated by various modern techniques. 5’-dGMP with Cp2TiCI2 or cis-RDT forms
chelate complexes in which both N and phosphate of dGMP bind to the metal center.
Whereas Cp2ZrCI2 and all the diorganotin compounds can bind dGMP only via the phosphate
group. The investigations of the interactions between Cp2TiCI2 or (C2H)2SnCI2 and DNA indicate
that there are two types of binding sites on DNA for Cp2TiCI2, i.e., the base nitrogen rings and
the phosphate group, while (C2H)2SnCI2 can bind to DNA only via the phosphate group. At last,
by carefully comparing and analysing the binding modes-activity relationships of the above
anticancer complexes and other non-platinum and platinum anticancer complexes, a hypothesis
named "Two-Pole Complementary Principle" was put forward.
1. Introduction
Metal complexes are promising compounds for the design of new anticancer agents.
Cis-diaminodichloro-platinum(ll) (cisplatin) and cis-diamine (cyclobutane-l,l-dicarboxylato)
platinum(ll) (carboplatin) are the first antitumor drugs in clinical use[1]. In order to overcome
clinical problems associated with the relatively limited activity of cisplatin and carboplatin against
the broad spectrum of human malignancies, acquired resistance, and side effects, a lot of new
non-platinum metal-based anticancer complexes have been developed. Among them, some
compounds containing Ti, V, Mo, Ru as metal center atoms have shown good antitumor activity
and remarkable low toxicity; and some diorganotin(IV) complexes have been found to be
effective against lymphocytic leukemia P388 cells in mice, which makes them interesting for
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possible clinical use[z].
Biological studies have shown that DNA is the primary cellular target for these metal-based
drugs[,r’-e]. Intensive efforts of various research groups in recent years have contributed
significantly toward an improved understanding of the mechanism of the antitumor activity of
platinum complexes[1,,]. However, significantly less is known about the antitumor mechanisms
of non-platinum metal-based complexes.
A main goal of our research has been to elucidate the aqueous coordination chemistry of
non-platinum metal-based anticancer complexes with nucleotides and their DNA binding modes.
These results should be valuable in understanding the mechanism of antitumor activity, as well
as laying the foundation for rational design of more active and less toxic metal drugs.
In this paper, we present the reactions of some typical antitumor agents, CpTiCI (Cp=
q -CsH), CpZrCI, cis-Ru"CI(DMSO) (DMSO) (cis-RDT), (CH)SnCI, (CH)_SnCI and
(CH5)2SnCl(phen) (phen=Phenanthroline), with DNA and its components, and report their
coordination chemistry investigations in aqueous solution with nucleotides, as well as their
bindings to DNA under near physiological condition. The possible molecular mechanism modes
of action are investigated and discussed as well as some rules of binding modes-activity
relationships of metal antitumor drugs are inferred and discussed.
2. Experimental
The antitumor agents CpTiCI(TDC), cis-RDT, (CH)SnCI, (CH)SnCI and
(CH)SnCl(phen) were prepared and purified according to the literature methods[1-1],
CpZrCI2 and (CH)SnCI, were purchased from Aldrich Chemical Company. The NMR
recognition probe, [trans-enOs( q -H)](CFSO) ,was a generous gift from Professor H. Taube
and Dr. Zaiwei Li, Stanford University, CA, the nucleotides, 2’-deoxyguanosine-5’-
monophosphat (dGMP), adenosine-5’-monophosphate (AMP) were purchased from Sigma
Chemical Company. Ethidium bromide(EthBr) was obtained from Fluca(Buchs, Switzerland). All
other reagents and solvents were analytical reagents grades.
H,P NMR spectra were recorded on a Bruker AM-500MHz NMR spectrometer or a
VXR-300 MHz NMR spectrometer in DO, proton chemical shifts are referenced to DSS as
internal standard, and phosphorous chemical shifts are referenced to 85% HPO as external
standard. UV and CD spectra were recorded on a Shimadzu UV-365 spectrophotometer and a
JASCO J-500C spectrophotometer using lcm quartz cuvette. The fluorescence spectra were
performed on a Hitachi Model-850 spectra fluorometer using 1 cm quartz cuvette, excitation
wave length was set at 520 nm. The entrance and exit monochromator slit widths were adjusted
to 0.5 nm. All pH measurements were carried out on a Beckman 50 pH meter. All reported
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pD values in D20 are corrected to pH readings(pD=pH-t 0.44). The cyclic Voltammetric
measurements were performed with a BAS-100A electrochemistry analytical instrument, an
Ag/AgCI electrode was used as the reference electrode with Pt as the auxiliary electrode, and a
hanging mercury drop electrode was chose as the working electrode.
3. Results and Discussion
The objective of the investigation was the solution characterization of aqueous
antitumor metal agents-nucleotide coordination chemistry and the elucidating of the possible
molecular mechanism mode of action between metal agents with DNA. We begin with a
discussion of metal drugs aqueous coordination chemistry with dGMP using [trans-enOs( q-
H)](CFSO) as a H NMR recognition probe followed by high-resolution H, P,C NMR
spectroscopy, and then we discuss the interactions between metal drugs with DNA under near
physiological conditions. At last, the relationships between the modes of action of drugs and
their anticancer activities and some rules are put forward.
3.1 Aqueous metal agents coordination with dGMP
The probe, trans-en Os (q -H) ]/ (scheme1), as previously demonstrated[], bind
readily to a variety of biomolecules such as nucleotides with ligand, L, substituted by these
biomolecules, that results in the direct coordination of Os to the donor atoms(such as N,O) of
the biomolecules. In each case the binding leads to characteristic H NMR spectrum for the
dihydrogen unit that appears in a spectral window in the range =0 to -20.
scheme1
When dGMP was added to solution of the probe in D20 at 25C each solute at 0.01 moll L,
the phosphate oxygen and N of dGMP both coordinated to the probe, the former being
dynamically preferred (K=3 1) and the interaction was complete after 10 min, while the latter
is thermodynamically preferred (K=2.9 10) and binding was complete after 24h. Figure 1
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clearly shows the reaction process. The peaks at 6=-13.16 and -13.56 grow in 10 min,
corresponding to D20 binding and phosphate oxygen binding, respectively. Meanwhile, a peak
at = -9.73, already discernible after 10min(Fig. la), continues to grows at the expense of the
others. This peak is assigned to the Nz binding. There is a competing reaction between D20
bonding, phosphate binding and N binding, which is not completely at equilibrium in 10 min. The
affinity of Os" for the DO and phosphate is not high and the conversion from DO binding and
phosphate binding to Nz binding is almost complete after 24h (Fig l b). Usually the binding of an
antitumor metallic agent to dGMP is via N or the phosphate group of dGMP, therefore, if an
antitumor metal agent is added to the probe-dGMP binary system, it will compete for the binding
sites of dGMP with the probe, and the characteristic peaks due to binding of the probe with
phosphate or N of dGMP will change. According to these changes, the binding sites of the
anticancer metal drugs to dGMP can be determined.
-8.0 -9.0 -10. 0 -I I. 0 -12.0 -13.0
ppm
Figure 2. Proton NMR spectra (500MHz) of the probe with dGMP and Cp2TiCl2 in D20
(a) After 20 min (b) After 24 hours drug: dGMP: probe=l: 1: 1, dGMP 0.010mol/L, pD=6.14
When dGMP, Cp2TiCI2 and the probe were mixed at the same time at 25C (Figure 2a,
b) the peaks due to the phosphate binding(-13.56) disappears completely 10 min after mixing,
and the peak due to N binding is much lower than that of the probe-dGMP binary system. This
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indicates that Ti completely occupies phosphate oxygen sites and partially occupies Nz sites of
dGMP. After 24h, cis-isomer of probe binding to Nz does not appear, which shows that Ti
hinders the binding of probe to N. These indicate bindings of Ti to both phosphate and Nz.
While in the ternary system of Cp2ZrCI2-probe-dGMP, only the peaks due to the phosphate
binding disappear, the peaks due toN binding is not affected at all during the reaction process,
suggesting Zr only coordination to phosphate of dGMP but not N.
Figure 3. Proton NMR spectra (300MHz) of the probe with dGMP and
cis-RDT in D20 (a) After 20 min (b) After 24 hours
In the ternary system of cis-Ru (DMSO)CI2-probe- GMP (Fig.3a, b) both of the peaks due
to the phosphate binding and Nz binding diminished obviously in intensity after 10 min (Fig.3a)
and 24h compared with those of the GMP-probe binary system. This indicate that both
phosphate oxygen and Nz of dGMP are coordinated to Ru.
-9.0 -I0’0 ::i;:O :--i: 0 -13.0
PPM
Figure 4. Proton NMR spectra (500MHz) of the probe with dGMP and Et2SnCI2 in D20
(a) After 20 min (b) After 24 hours drug dGMP" probe=l" 1" 1, dGMP 0.005 mol/L, pD=7.44
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As diorganotin agents, both fresh prepared and old prepared (has been prepared for
three months) solutions of Et2SnCI2 were used. In the ternary system of Et2SnCI2(fresh)-probe-
dGMP (Fig.4a, b), the case is just the same as that in Cp2ZrCI2-probe-dGMP trinary system.
(m)
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Figure 5. Proton NMR spectra (500MHz) of the probe with dGMP and Et2SnCI2 (have been prepared for long
time) in D20 (a) After 20 min, (b) After 4 hours drug: dGMP: probe=l 1" 1, dGMP 0.005 mol/L, pD=7.44
-8. 0 -0.0 -10. 0 -f f. 0 -12. O -13.0
ppm
Figure 6. Proton NMR spectra (500MHz) of the probe with dGMP and Et2SnCI2(phen) in D20
(a) After 20 min (b) After 24 hours drug: dGMP: probe=l" 1 1, dGMP 0.002mol/L, pD=6o44
When old Et2SnCI2 is used in place of fresh Et2SnCI2(Fig.5a, b), we find that old Et2SnCI2
does little effect on the binding of probe to phosphate or NT. This suggest that fresh Sn can only
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coordinate to phosphate but not to N of dGMP, while old Sn can coordinate to neither
phosphate nor N of d GMP. When fresh Et2SnCI2 (phen) were in place of fresh Et2SnCI2,
NMR results are shown in Fig.6a, b. We can find that Et2 (phen)Sn2(IV) can only bind to
phosphate of dGMP but not to N.
In all the above figures, we can find a new peak at 6 = -13.23 ppm appears after drug-
dGMP interaction. The peak is assigned to CI-binding to the probe. This indicates that all the
above metal complexes dissociate in water with the cis-chloro atom as leaving group.
H, 3p, C NMR data (Table 1) provide further support for the above results. H NMR
spectra of dGMP Na alone shows a singlet at 7.93 ppm corresponding to the C(8) protons.
When anticancer metal complex (0.01mol/L was incubated with 5’-dGMP (or 5’-GMP) in a 1:
1 molar ratio in DO at 25C, examination of reaction mixtures by H NMR find that downfield
position of the new H signals appears for Cp2TiCI2, cis-RDT, but not for Cp2ZrCI2, Et2SnCI2,
EtSnCI2 (phen). The down field shift of H8 signals suggests Nz coordination in Cp2TiCI2-dGMP
system and cis-RDT-GMP system.C NMR data indicate that the signals of C(6) and C(8) are
not changed when dGMP have been incubated with Et2SnCI2 or Et2SnCI2(phen) for 24h, further
demonstrating N or O6 of dGMP is not coordinated to Sn(IV).
Table 1.
the reaction with metal anticancer complexes
NMR spectroscopic data (ppm) for dGMP(Na2)(or GMP Na2) involved in
Compounds
dGM,PNa
dGMPNa;t: Et=SnClz (1"1)
dGMPNa;: EtSnCl=(phen) (1:1)
dGMPNaz: Cp=TiCIz (1 "1 )
dGMPNa= Cp.rClz (1:1)
H(8)
7..93(s)
.7.87(S).
7.84(s)
8.43
8.14
7.98
:8.20
8.00
dGMPNa= cis-RDT (1-1 )
H(I’)
6.08(d).
6.10(d).
6.00(d)
3;81(s)
-!,.;09(s),,
.1.62(S)
6.15
2.96
1.50
12.9
11.29
13C(8),
115.33
115.58
13C(;)
158.15
158.44
s=singlet, d=doublet.
TheP NMR data also establish phosphate group coordination to all the metal drugs tested.
The free dGMPNa shows a singlet at 3.81ppm, in theP NMR spectra, this peak is shifted
either upfield or downfield upon addition of the five metal complexes, respectively, this suggest
that the five metal complexes are directly bind to dGMP(or GMP) via phosphate group.
The above results suggest that the interactions between dGMP(GMP) with Cp2TiCI or cis-
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RDT yield chelate complexes with Nz and phosphate coordination, while interactions between
dGMP with Cp2ZrCI2, Et2SnCI2, Et2SnCI2(phen) yield complexes with only phosphate
coordination.
3.2 Interactions between Metal Complexes and DNA
By means of UV, CD, flLorescence spectra and CV, we investigated the interaction of two
typical metal complexes,CpTiCl and EtSnCI ,with calf thymus DNA and salmon DNA. The
results show that there are two types of binding sites between DNA and CpTiCI, one is the
phosphate group of DNA and the other is the base nitrogen rings of DNA whereas only the
phosphate group on DNA can binds to EtSnCI.
2.4
2.0
1.6
1.2
0.4
220 240 260 20 3on 320
,! (nm
____.l___-
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0.50
O.4O
0.30
0.20
0. I0
Figure 7. The effects of Cp2TiCI2 on the absorption
spectra of calf thymus DNA,
1--5, Rt; 1.66, 0.83, 0.42, 0, 0.21
Figure 8. UV absorption change of the mixture of
Et2SnCI and DNA with the drug concentrations.
1-6, Rt: 0, 0.2, 0.5, 1.0, 2.0, 4.0, respectively.
UVspectra
Figure 7 shows the absorption spectra of DNA alone in the presence of CpTiCI with
various concentration in 0.1 mol/L NaCI(pH=7.2) after they reacted in dark at 37C for 48h (the
absorption of CpTiCI solution as background When Rt (=Cc/CD()) is low typical
"hypochromic effect "occurs, when Rt is high, typical "hyperchromic effect" of DNA appears.
Hypochromism results from the contraction of DNA in the helix axis, as well as from the change
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in conformation on DNA, while hyperchromism results from the damage of DNA double-helix
structure. It is indicated from Fig.7 that CpTiCI binds to phosphate group of DNA backbone at
low Rt and to the base nitrogen rings of DNA at high Rt to damage the duplex structure of DNA.
If Cp2TiCI is replace by EtSnCI, the UV spectra shown in Fig.8 demonstrates that EtSnCI
can only cause DNA hypochromism but not hyperchromism. This result indicates that Et2SnCI2
can induce the contraction in DNA helix but can not destroy the double helix structure of DNA.
This result also reflect that EtSnCI only binds with the phosphate group of DNA. In addition, we
discover that the phosphate group ions can markedly inhibit the interaction of EtSnCI with DNA.
This also supports the conclusion that EtSnCI only binds with the phosphate group of DNA.
CD spectra
Fig.9 shows the CD spectra of DNA in the presence of CpTiCI with various
concentrations in 0.01 mol/L KNO after they reacted in the dark at 37C for 48h. The CD bands
show no great change at low R(=0.25 or 0.50), but a small diminution of the intensity of negative
bands as well as a little increase and blue shift of the positive bands. The changes suggest the
transition of B-DNA to A-DNA[], which indicates that DNA is contracted by CpTiCI, supporting
the conclusion of UV spectra.
200 220 240 ")6() 280 3()0 320
Figure 9. The effects of CP2TiCl on the CD spectra of thymus DNA.
1--5, Rt 0, 0.25, 0.50, 1.0, 2.0.
The CD band changes inversely when Rt=l, and there is a red shift from 273nm to 279nm
for positive CD band and 237nm to 243 nm for negative CD band, both losing intensity seriously,
which suggests a decrease in helixity and denaturation of DNA uz,e], indicating that binding of
Cp=TiCI with DNA base nitrogen rings occurs, when Rt=2, there is a little precipitate in the
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solution. The CD spectrum of the filtrate is recorded. The CD band changes greatly, the
negative band almost disappears completely and a new positive band at 234 nm appears, which
confirms that CpTiCI binds with the bases to cause the denaturation of DNA at high Rt.
Fluorescence studies
The measurement of EthBr binding to DNA metal complexes was studied by an increase
of EthBr fluorescence Il. The method essentially consists of titrating a given amount of DNA-
metal complex with increasing concentration of EthBr and measuring the change in
fluorescence intensity. The characteristics of the binding of EthBr to DNA can be expressed by
Scatchard equation [19]:
r/C=K(n-r)
Here, r is the molar ratio of bound EthBr per nucleic acid phosphate, n the number of
binding sites per nucleic acid, K, the intrinsic association constant to a site, and C, the free EthBr
concentration. We can obtain straightline Scatchard plots using a function of r, and distinguish
the drug action mode by using the Scatchard plots in the presence of drug [19,20].
24
0.05 0 0.15
Figure 10. Scatchard plots. With the decrease of intercept on r axis
of the curves, Rt" 0, 0.25, 0.5, 1.0 and 2.0, respectively.
Fluorescence Scatchard plots for the binding of EthBr to solution DNA in the presence of
varying concentration of CpTiCI are given in Fig. 10. At low concentration of drug (Rt=0.25), we
observed uncompetitive inhibition of EthBr binding to DNA pol. Here, only the intercept of the
abscissa, which is the number of binding sites per nucleotide (n), decreases, whereas the slope
or the association constant (K) remains constant. This uncompetitive inhibition is probably due
to binding of the drug to the phosphate group of DNA. At high concentration (R=0.5, 1), the
Scatchard plots fit mixed mode in which K and n values both change, this means both
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competing and uncompeting modes exist at these Rts. This indicates that Cp2TiCl2 has two
types of binding sites on DNA= that is say, besides binding to the phosphate, Cp2TiCI2 may
bind to DNA on it’s base nitrogen rings. Especially at R=0.5, the Scatchard plots are similar to
that of RNA-EthBr or A-DNA-EthBr complexes[91. This further implies that the double helix of
DNA decreases, the secondary structure has changed with the conformation transferring from
B-form to A-form. This conclusion is also confirmed by CD spectra shown above. At Rt=l, there
are few binding sites(n < 0.01) on DNA for EthBr, indicating the double helix structure of DNA
has been badly damaged.
CVstudy
CV method is one of the powerful methods that elucidate the interaction modes between
drugs and DNA[]. Native DNA is not reducible at the mercury electrode because the stability
of the intact double helix makes the reducible bases inaccessible to the electrode. In Hepes
buffer, pH=7.0, the addition of DNA cause the peak potentials of EtSnCI2, Ep and Epa both to
be shifted to more positive values, while the peak currents keep the same, as shown in Figure
11. The obvious positive shift of peak potentials indicates the binding between drug and the
phosphate of DNA[2,221. Here, this mode may be the binding between Sn and DNA via only the
phosphate group of DNA.
0 80
V/mV
Figure 11. Cyclic voltammogram of 0.45 mM Et2SnCI2
(1) in the absence and (2)in the presence of DNA (0.45 mM nudeotide phosphate).
Supporting electrolyte 50 mM KNO3, 5 mM Hepes, pH=7.0, Sweep rate, 200 mv/s.
Making a comparison between the binding modes with dGMP and DNA for the five
antitumor metal complexes, we can find that CpTiCI and cis-RDT are similar, they both bind to
dGMP(or DNA) by the metal center coordinating with the phosphate oxygen and N of dGMP,
and the binding modes of CpZrCI, (CH)SnCI and (CH)SnCl(phen) are similar, they all
only bind to dGMP (or DNA) by the metal center coordinating with the phosphate oxygen. It is
very interesting if we relate the binding modes with their anticancer activities. CpTiCI and cis-
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RDT both are highly active anticancer agents with a wide antitumor spectrum, while CpZrCI,
(CH)SnCI and (CH)SnCl(phen) are not good anticancer agents, (CH)SnCI and
(C2H)2SnCI2(phen)can only inhibit P388 cell growth and CpZrCI has no activity at all. Studies
on the binding modes of other high active anticancer metal agents, such as cisplatin and
CP2MoCI, also revealed that they can both bind with phosphate group and base Nz of DNA or
nucleotides[,]. Although binding of metal ions to the sugar ring oxygen atoms has rarely been
observed, Pt-phosphate interactions do occur in certain cases[-z]. The role of phosphate under
physiological conditions seems to be only secondary for coordination nevertheless, it is quite
important for hydrogen bonding, and the binding between metal ion and phosphate might be the
first step of metal agents-DNA(or nucleotides) interactions, just as in the case of CpTiCI-DNA
interaction. Definitive NMR evidence was presented that there has Nz, (z PO chelate species[z]
in the mixture of 5’-GMP and cisplatin. Marzilli and coworkersI] reported conclusive evidence
from a multinuclear NMR study, supported by a molecular mechanics calculation, that in dilute
(5-30 mM) neutral DO solutions, the preferred 1:1 complexes formed between cis-
Pt(ND2CH)(DO) and purine 5’-NTP, are monomeric macrochelates of the type cis-
Pt( ND2CH)2 (5’-NTP-Nz, 7 PO) where the nucleotide is bound via Nz and an oxygen atom of
the 7 -phosphate group. Such species were observed as intermediates during the course of the
reaction when r(Pt/NTP)= 0.5 and were the major products formed at 2> r > 1. Indeed, more
and more unambiguous N, (z PO chelate complexes have been reported by studying
interactions between active anticancer metal complex and nucleotides. Marks and coworkers
[,2! has reported the interactions between anticancer CpMoCI_ and 5’-AMP yield a N, PO
chelate Mo(CsH)(5’-AMP-N,( PO). The crystal structure of [CpMo(5’-dGMP)] provides a
further example of binuclear N ,PO chelation[]. Interactions between antimetastatic agents
trans-RuCl (DMSO) and 5’-dGMP also forms N, PO chelation[]. So that the binding
modes with DNA of a metal complex seem play a key role in its anticancer activity. It seems all
highly active anticancer metal drugs has the ability to bind with both phosphate group and
nitrogen sites on bases of DNA. As everybody knows, chemical activities of a compound are
determined by its molecular structure. So we should make further analysis on the relationships
between the structure of metal anticancer agents, the binding modes with DNA and their
anticancer activities.
DNAs are the target molecules for most of the metal anticancer agents in human body.
The anticancer nature is the coordination of metal ions with DNA molecules, i.e. the direct
chelation of the metal ions with certain nucleophilic groups in DNA (such as oxygen sites from
phosphates and nitrogen as well as oxygen sites from bases), causing the DNAs’ damage in
cancer cells, the DNAs were hindered during the processes of replication or transcription, the
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growing and division of the cancer cells were stopped, and resulted in their death.
When drug molecules (pre-anticancer molecules) enter into an organism, they will first
undergo a series of processes including hydrolysis, transport and membrane-crossing, and then
reach the nearby of target DNA molecule and form active intermediates which interact with DNA
molecules directly and exert the anticancer activity. These active intermediates have a general
cis-form of two-water-binding transitional state:
[ciS-AnM(H20)2]m/,
A is stably binding hydrophobic group, n=l, 2 or more;
M is metal ion,
The number of water molecules binding to M must not be fewer than two and they must be
lie in the ortho-position of the structure
The functions of the hydrophobic ligand A are:
(1) caring the whole molecule to cross membranes (including cell membranes and
nucleus membranes), go through the bilipid bilayers;
(2) making the metal ion to move to the nearby of the base’s cyclic-nitrogen sites and form
covalent bonding.
Metal anticancer complexes are often electrophilic and may react with many cellular
components, such as simple ions and molecules like (31-, (HPO)2-, OH- and H20; amino acids,
peptides and polyphosphates like His, Met, Cys, glutathione, metallothionein and ATP. Viewing
from the coordination chemistry, metal complexes (including those of Pt) can bind to several
types of possible biomolecules in the cell. But only the binding on DNA which lead to cell death
is considered the most important. In the case of platnium complexes, it is quite clear that in the
cells, after the relatively slow hydrolysis, cis-Pt have a preference for DNA over proteins and
other molecules. Sadler and co-workers have shown that L-methionine increases the rate of
reaction of 5’-GMP with cisplatin and that S-bound L-HMet in the adduct [Pt(dien)(L-HMet-S)]
2/
(dien=l,5-diamino-3-aazapentane) can be replaced by N7 of 5’GMPp-]. This work, together
with the results of van Boom and Reedijki, who reported the intramolecular displacement of a
Pt-bound thioether by a guanine nucleobase, suggest that novel routes to DNA platination from
anticancer drugs may exit. Therefore it is conceivable that a methionine-containing protein or
peptide could transport and transfer some platinum to DNAp].
Thus, in a very simple model, the action process of a metal anticancer agent in an organism
may be briefly summarized into following equations
DX2 + 2H20 ====[D(H20)2]
2, + 2X
[D(H20)2] 2* + DNA ==== [DNA-D]
2/ + 2H20
(1)
(2)
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DX2 is the pre-anticancer molecule,
[D(H20)2]
2/ is its active intermediate produced by hydrolysis,
DNA-D is DNA-drug complex.
DNA molecule is a two-pole molecule. Its surface is a negatively-charged backbone of
phosphatepentose chains, in the inside of double helix there exist hydrophobic bases stacking
layer by layer. For exerting its potency, the drug molecules must bind with the phosphate
groups of DNA at first, and then, with the help of DNA’ conformational dynamic changes (say,
partial unwinding of the double helix), the lipophilic groups of the drug molecule may be drawn
by DNA’s hydrophobic sections, the nitrogen sites on DNA molecules may be exposed, the
metal atom could invade into the internal part of DNA and coordinates with the bases. Oxygen
site on the phosphate group has a higher negative charge relatively, it is a good donor with high
electronegativity; so its action with the metal atom was caused mainly by static electricity,
forming electrovalency, belongs to charge-controlling reaction.
Nitrogen atoms on the bases are donors with lower electronegativity, they react with the
metal atom to form covalent bonds, belonging to orbital-controlling reactions.
It appears that these two interactions were brought forth one after another and coexisted.
This interaction mode is in conformity with the principle of multiple binding by flexible fitting and
maximum bonding, such a principle is generally accepted when the biochemical reactions are
considered.
Through the study on hydrolysis mechanism and relationship between structure and
activity of metal anticancer agents, we think that the following three points are key if the metal
anticancer agents have activities:
(1) Appropriate hydrolysis rates of a complex;
(2) Forming the active intermediate [cis-AM(HO)]n/,
(3) Forming of the coordination both with the oxygen of phosphate groups and with
nitrogen of bases.
The molecules with high anticancer activities should not only produce active intermediates
by the proper hydrolysis rates, but also bind to both oxygen of phosphate groups and nitrogen of
bases in DNA, thus showing anticancer activity.
3.3 Two.Pole Complementary Principle (TPCP)
The similarities in chemical features of high active metal complexes infer that there must
be some structural similarities in their molecular level. After comparison the structure-activity
55Vol. 5, No. 1, 1998 Interaction ofSome Non-Platinum Metal Anticancer Complexes with Nucleotides
andDNA and the Two-Pole Complementary Principle(TPCP) Arising Therefrom
relationships of more than 200 metal anticancer complexes, including platinum complexes, we
find they actually have some common structural features and acting laws for the molecules of
metal anticancer agents. We generalize these factors into a rule named Two-Pole
Complementary Principle(TPCP), which includes three aspects:
(1) Two-pole complement in molecular structures:
The drug molecules with anticancer activity always have two poles of hydrophilicity and
hydrophobicity, positive and negative charges in their structures. Correspondingly, they will
present easily-leaving groups and stable keeping groups in a solution. Such two-pole structures
can lead the drug molecules not only to be di.solved in water and transported to the surface of
the cell membranes, but also to cross the membranes by going through the lipid bilayers and
arrive at the nearby of the target molecules.
(2) Two-pole complement in the receptor-substrate action mode:
The interaction between the drug molecule and its target molecule is always executed by
forming an active intermediate which binds with oxygen sites (electrovalently) on phosphate
groups and nitrogen sites (covalently) on purines, pyrimidines of DNA backbone through
charge-controlling and orbital-controlling. That is a two-pole complement of electrovalent and
covalent action modes.
(3) Two-pole complement in the symmetry of the receptor-substrate system:
The interaction characteristics of a chiral drug molecule with DNA behave as using the left
hand enantiomer of the drug molecule binding with the right hand DNA, forming a two-pole
complementary complex chirally.
From the above principles we can extend criteria which are used for assessment of activity
of metal anticancer agents as follows:
(1) For the active intermediate of an anticancer agent molecule, its dipole moment does
not equal to zero, i.e.
(2)The drug molecule should possesses both hydrophilic and hyrdophobic groups
simultaneously. In an homologue of drugs, proper oil/water partition coefficients are needed and
the hydrophobic group should not be too bulky.
(3) In the physiological liquid the drug molecule should have appropriate hydrolysis rate
constants and at the near of DNA an active intermediate should combine at least two water
molecules in cis-configuration.
(4) The metal ion of the interactive center must have appropriate Pearson hard-soft degree
(i.e. proper valence and radium) as well as abundant valence shell orbital so that it may have an
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affinity not only for DNA’s oxygen site on phosphate to form electrovalent bond but also for
nitrogen sites on purine, pyrimidine to form covalent bond.
(5) The chiral drug molecule should be left hand enantiomer so that it can form a
complementary structure with DNA molecule which is right hand chiral.
The above TPCP has generalized the molecular structure, action modes and steric
selectivity for metal anticancer agents. This principle has some guidance for the design and
synthesis of new metal antitumor drugs. However, for numerous various metal antitumor
complexes, the action mechanisms may differ dramatically, and there are always some complex
can’t be accorded with the TPC Principle. And the TPC Principle itself may still has some
incomplete aspects, and need to be further studied to make it more complete.
Acknowledgment.
The authors gratefully acknowledge Professor H.Taube and Dr. Zaiwei Li(Stanford
University, CA) for their generous gift of the probe. The financial support from National Nature
Science Foundation of China, National Nature Science Foundation of Shanxi Province, the
Youth Science Foundation of Shanxi Province and the financial support from Shanxi Education
Commission are greatly acknowledged.
Reference
1. J. Reedijk, Handbook of MetaI-Ligand Interaction in Biological Fluids,Bio#organic Chemistry,
Vol. 2(G. Berthon Ed.) Marcel Dekker, Inc. p.967-989.(1995)
2. A.K. Saxena, F. Huber, Coord. Chem. Rev. 95, 109(1989)
3. P. Koepf-Maier, H. Kopef, Chem. Rev. 87, 1137(1987)
4. G. Sava, S. Zorzet, T.Giraldi, G. Eur. Zassinovich, J. Cancer. Clin. QncioL 20, 841 (1984)
5. P. Koepf-Maier and D. Krahl, Naturwiss 68, 273 (1981)
6. M.J. Clarke, Prog. Clin. Bioclem. Med. 10, 25 (1989)
7. A.S. Gonza, J. S. Casas, J. Sordo, J. Inorg. Biochem. 39, 227(1990)
8. J. Reedijk, Pure & Appl. Chem. 59, 181(1987)
9. K.J. Barnham, S. J. Berners-Price, Zo Guo, P d. S. Murdoch, P. J. Sadler, Platinum and
Other Metal Coordination Compounds in Cancer Chemothererapy 2, H. M. Pinedo and J.
H. Schornagel Ed.), Plenum Press, New York, pp 1-16 (1996)
10. W.I. Sundquist and S. J. Lippard, Coord. Chem. Rev. 100, 293(1990)
11. G.Wilkinson, J. M. Birmingham, J. Am. Chem. Soc. 76, 4281 (1954)
12. I.P.Evans, A.Spencer, and G.Wilkenson, J. Chem. Soc., Dalton Trans. 7,204 (1973)
5?Vol. 5, No. 1, 1998 Interaction ofSome Non-Platinum Metal Anticancer Complexes with Nucleotides
andDNA and the Two-Pole Complementary Principle(TPCP) Arising Therefrom
13. P. Newmann, Annaler, 653, 157 (1962)
14. A.J. Crowe, P. J. Smith, J. Organomet. Chem. 224, 223 (1982)
15. Z.W. Li, H. Taube, Science 256, 210 (1992)
16. V.l.lvanov, et al., Biopo/ymers, 12, 89(1973)
17. M.J.Clarke,,et al., Inorg. Chim. Acta 124, 13 (1986)
18. Zi-xian Lu et al., Application of Circular Dicroism and Optical Rotatory Dispersion in
Molecular Biology, Science Pree, Beijing(1987)
J.B. Lepeoq, C. Paoletti, J. Mol. Biol. 27, 87(1967)
M. Howe-Grant, K.C. Wu, W.R. Bauer, and S.J. Lippard, Biochemistry 15, 4339(1976)
M.T. Carte and A.J. Bard, J. Am. Chem. Soc. 109, 7528(1987)
J. Sun and D.K. Solaiman, J. Inorg. Biochem. 4, 271 (1990)
P. Umapathy, Coord. Chem. Rev. 95, 129(1989)
L.Y. Kuo, M.G. Kanatzidis, M. Sabat, A.L.Tipton and ToJ.Marks, J. Am. Chem. Soc. 113,
9027(1991)
R.N. Bose, R.D. Cornelius and R.E. Viola, J. Am. Chem. Soc. 108, 403(1986)
T.G. Applaton, J.R. Hall, D.W. Neale and S.F. Ralph, /non2. Chem. 25, 720(1986)
M.D. Reily and L.G. Marzilli, J. Am. Chem. Soc. 108, 8299 (1986)
M.D. Reily, T.W. Hambley and L.G. Marzilli, J. Am. Chem. Soc. 110, 2999(1988)
L.Y. Kuo, M.G. Kanatzidis and T.J. Marks, J. Am. Chem. Soc. 109, 7207(1987)
E. Alessio, Y.Xu, S. Cauci, G. Mestroni, F. Quadrifoglio, P.Viglino, L.G. Marzilli,
J. Am. Chem. Soc. 111, 7068 (1989)
31. K.J. Barnham, M. I. Djuran, P. d. S. Murdoch, P. J. Sadler, J. Chem. Soc. Chem Commun.
721(1994)
32. K.J. Barnham, M. Io Djuran, P. d. S. Murdoch, J. D. Ranford, P. J. Sadler,
J. Chem. Soc. Dalton Trans. 3721 (1995)
33. K.J. Barnham, M. I. Djuran, P. d. S. Murdoch, J. D. Ranford, P. J. Sadler,
Inorg. Chem. 35, 1065(1996)
34. S.S.G.E. van Boom and J. Reedijk, J. Chem. Soc. Chem. Commun. 1397(1993)
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Received" August 8, 1997- Accepted" August 25, 1997-
Received in revised camera-ready format" January 19, 1998
58